OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
23 apr 2008 - 18:02
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus presents positive Locteron Phase IIa study results at EASL conference
Bericht
OctoPlus N.V. (“OctoPlus”) (Euronext: OCTO), the drug delivery and development company, announces that extended results from its successful SELECT-1 Phase IIa clinical trial of Locteron® for the treatment of chronic hepatitis C (HCV) will be presented today at the 43rd Annual Meeting of the European Association for the Study of Liver Diseases (EASL). The poster presentation titled “Viral Kinetics during Treatment with a Controlled-Release Recombinant Interferon Alfa-2b in Genotype 1 Chronic Hepatitis C Patients” is presented in Category 5h.
The study results presented at EASL show a strong and statistically significant effect of Locteron on the amount of HCV virus particles, and this effect increased with higher doses. Patients receiving Locteron experienced side effects that were less frequent and less severe than those previously reported in clinical trials for other interferons. Biomarker results demonstrate Locteron’s biological activity with sustained presence of interferon alfa in the body, and showed improvement of liver function in terms of liver enzyme test results.
Datum laatste update: 19 december 2025